Table 1.
Patient characteristics.
Fig 1.
Flow diagram for patient recruitment, enrolment and participation in the study.
Fig 2.
Change in (A) t-PA and (B) PAI-1 antigen in arterial and venous blood samples post-angiography compared to baseline in patients receiving iohexol and iodixanol.
There was no significant difference between the groups (2-way repeated measures ANOVA, P value shown is between treatment groups; n = 6 in each group). There was no interaction between treatment groups and arterial/venous plasma.
Fig 3.
Change in (A) t-PA and (B) PAI-1 activity in arterial and venous blood samples post angiography compared to baseline in patients receiving iohexol and iodixanol.
t-PA activity was significantly reduced in the iohexol group; PAI-1 activity was significantly reduced in the iodixanol group (2-way repeated measures ANOVA, P value shown is between treatment groups; n = 6 in each group). There was no interaction between treatment groups and arterial/venous plasma.
Fig 4.
Effect of angiography (post-angio) on platelet-monocyte conjugation in patients exposed to (A) iohexol and (B) iodixanol compared to baseline (pre-CA); *P<0.05. The % reduction in platelet-monocyte conjugation is shown in (C). n = 6 in each group; NS—P>0.05.
Fig 5.
(A) In vitro oxygen-centred free radical generation in samples of CA at 37°C. Iohexol generates free radicals at a significantly higher rate than iodixanol (n = 4; P<0.001). (B) Representative EPR spectra obtained for iodixanol alone, iodixanol + vitamin C (200 μM) and iohexol after 60 min incubation (37°C) with the oxygen-centred radical spin trap, tempone-H (1 mM). The characteristic 3-line spectrum is representative of formation of the stable radical adduct, 4-oxo-tempone, via reaction with oxygen-centred radicals; the amplitude of the signal is proportional to the amount of 4-oxo-tempone present.